Skip to main content

Table 1 Demographic and anthropometric data of enrolled participants

From: Evaluating the effect of recombinant human growth hormone treatment on sleep-related breathing disorders in toddlers with Prader–Willi syndrome: a one-year retrospective cohort study

 

non-rhGH (n = 17)

rhGH (n = 17)

p value

Genotype

  

0.71

 Paternal deletion (%)

11 (64.71)

13 (76.47)

 

 Aberrant methylation (mUPD and imprinting defect) (%)

6 (35.29)

4 (23.53)

 

Sex

  

> 0.05

 Male (%)

7 (41.12)

8 (47.06)

 

 Female (%)

10 (58.82)

9 (52.94)

 

Age (months)

25.23 ± 13.81

20.76 ± 9.22

0.59

Height/length (m)

0.84 ± 0.13

0.85 ± 0.08

0.81

Weight (kg)

13.65 ± 5.26

11.38 ± 3.12

0.43

W/H z-score

1.08 ± 1.97

-0.45 ± 1.27

0.02

Obesity and overweight (%)

6 (35.29)

1 (5.89)

0.03

IGF1 z-score

-0.46 ± 0.68

1.74 ± 1.75

< 0.001

IGFBP-3 (μg/mL)

2.17 ± 1.09

3.56 ± 1.24

0.003